Dr. Richard Naimark, a psychiatrist in private practice at Chestnut Hill Counseling in Dover, New Hampshire, relates a tidbit that tempers TCR’s fairly lukewarm review of Paxil CR.
Read More
The latest member of the “controlled-release club” is GlaxoSmithKline, with its Paxil CR. While cynics may believe that CR launches are simply efforts to prolong patent-lives and therefore profits, the reality is that CR formulations are generally better tolerated and easier to dose.
Read More
Celexa (Citalopram) has been used in Europe since the late 1980s, and since its introduction in the U.S. market in 1998 it has made steady inroads into the SSRI market, largely because it has the reputation of being unusually well tolerated.
Read More
… psychiatric research standards, the numbers were huge: 851 patients in the Effexor XR group, 748 in the SSRI group (Prozac, Paxil, and Luvox), and 446 in the placebo group. The doses of comparator SSRIs were robust enough to mirror what we actually use in clinical practice, and treatment duration...
Read More
America has not been kind to St. John’s Wort. In Europe, this flowering bush that blooms around June 24 (St. John’s Day), has been all the rage for about 2000 years. It was first mentioned by the Roman Pliny the Elder in the first century, and over the past two millennia it has been used for a variety of ills, including diarrhea, urinary problems, demonic exorcism, and more recently, for melancholia.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.